Background: Human leukocyte antigen G (HLA-G) is a nonclassical major histocompatibility complex class I gene. HLA-G stimulates Th2 cytokine secretion by peripheral blood mononuclear cells. The role of soluble HLA-G (sHLA-G) in bronchial asthma is incompletely understood and the plasma level of sHLA-G in asthmatic children has not been investigated. Objective: It was the aim of this study to investigate the plasma level of sHLA-G in asthmatic children. Methods: Asthmatic (n = 53) and healthy children (n = 16) were included in the study. Levels of sHLA-G were determined in plasma using ELISA. Spirometry, total immunoglobulin E and eosinophil counts were obtained and skin testing done with a battery of 25 antigens with appropriate positive and negative controls. Results: No significant difference was observed in the plasma level of sHLA-G between the asthmatic and healthy children (p > 0.05). When we compared atopic asthmatics with healthy controls, we found significantly higher levels of sHLA-G in atopic asthmatics (p < 0.05). There was a significant difference in the peripheral blood eosinophil counts and total immunoglobulin E levels among the groups (p < 0.001). Conclusion: Our study shows that plasma sHLA-G levels do not differ between asthmatic children and healthy controls. However, higher plasma levels of sHLA-G in atopic asthmatics may suggest a role for sHLA-G in atopy. Further investigations are required to better define the mechanism of the production and the role of sHLA-G molecules observed in patients with asthma.

Keywords:
Asthma, Atopy, Soluble human leukocyte antigen G
1.
Blaschitz A, Lenfant F, Mallet V, Hartmann M, Bensussan A, Geraghty DE, Le Bouteiller P, Dohr G: Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol 1997;27:3380.
2.
Ishitani A, Geraghty DE: Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 1992;89:3947.
3.
Fujii T, Ishitani A, Geraghty D: A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994;153:5516–5524.
4.
Nicolae D, Cox NJ, Lester LA, Schneider D, Tan Z, Billstrand C, Kuldanek S, Donfack J, Kogut P, Patel NM, Goodenbour J, Howard T, Wolf R, Koppelman GH, White SR, Parry R, Postma DS, Meyers D, Bleecker ER, Hunt JS, Solway J, Ober C: Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005;76:349–357.
5.
Meng H, Hou Y: Genetic polymorphisms, function and clinical effect of HLA-G. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002;19:350–353.
6.
Solier C, Aguerre-Girr M, Lenfant F, Campan A, Berrebi A, Rebmann V, Grosse-Wilde H, Le Bouteiller P: Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur J Immunol 2002;32:3576.
7.
Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H: Detection of HLA-G5 secreting cells. Hum Immunol 2003;64:1017–1024.
8.
Raghupathy R: Th1 type immunity is incompatible with successful pregnancy. Immunol Today 1997;18:478–482.
9.
Kapasi K, Albert SE, Yie S, Zavazava N, Librach CI: HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000;101:191–200.
10.
Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N: HLA-G: a shield against inflammatory aggression. Trends Immunol 2001;22:553–555.
11.
Maejima M, Fujii T, Kozurna S, Okai T, Shibata Y, Taketani Y: Presence of HLA-G-expressing cells modulates the ability of peripheral blood mononuclear cells to release cytokines. Am J Reprod Immunol 1997;38:79–82.
12.
Shiina T, Inoko H, Kulski JK: An update of the HLA genomic region, locus information and disease associations. Tissue Antigens 2004;64:631–649.
13.
Cookson W: Genetics and genomics of asthma and allergic diseases. Immunol Rev 2002;190:195–206.
14.
Global Initiative for Asthma: Global strategy for asthma management and prevention. Bethesda, Md. National Institutes of Health, National Heart Lung and Blood Institute, 2002.
15.
LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J, Carosella ED: Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003;62:273–284.
16.
Yang Y, Gerahty DE, Hunt JS: Cytokine regulation of HLA-G expression in human trophoblast cell lines. J Reprod Immunol 1995;29:179–195.
17.
Chu W, Yang Y, Geraghty DE: Interferons enhance HLA-G mRNA and protein in transfected mouse fibroblasts. J Reprod Immunol 1999;42:1–15.
18.
Moreau P, Faure O, Lefebvre S: Glucorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc 2001;33:2277–2280.
19.
Matsumoto K, Inoue H, Fukuyama S, Tsuda M, Ikegami T, Kibe A: Decrease of IL-10-producing T cells in the peripheral blood of severe unstable atopic asthmatics. Int Arch Allergy Immunol 2004;134:295–302.
20.
McIntire RH, Hunt JS: Antigen presenting cells and HLA-G. A review. Placenta 2005;26:104–109.
21.
Rebmann V, van der Ven K, Pabler M, Pfeiffer K, Krebs D, Grosse-Wilde H: Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001;57:15–21.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.